Cysteine Hydrochloride Patent Expiration
Cysteine Hydrochloride is used for treating patients needing parenteral nutrition through intravenous administration of a diluted cysteine hydrochloride solution. It was first introduced by Hospira Inc
Cysteine Hydrochloride Patents
Given below is the list of patents protecting Cysteine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Elcys | US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Elcys | US11969439 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Exela Pharma |
Nouress | US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10493051 | Cysteine composition and injection | Mar 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10543186 | Cysteine composition and injection | Mar 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10702490 | Cysteine composition and injection | Mar 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11045438 | Cysteine composition and injection | Mar 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | Mar 02, 2039 | Baxter Hlthcare Corp |
Nouress | US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Nouress | US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | Jan 15, 2039 | Baxter Hlthcare Corp |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Cysteine Hydrochloride Generics
Several generic applications have been filed for Cysteine Hydrochloride. The first generic version for Cysteine Hydrochloride was by Dr Reddys Laboratories Sa and was approved on Apr 8, 2022. And the latest generic version is by Hikma Pharmaceuticals Usa Inc and was approved on Jan 26, 2023.
Given below is the list of companies who have filed for Cysteine Hydrochloride generic.
1. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 1 generic for Cysteine Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
500MG/10ML (50MG/ML) | solution | Discontinued | INTRAVENOUS | N/A | Apr 8, 2022 |
2. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Cysteine Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
7.25% | injectable | Discontinued | INJECTION | N/A | Jan 26, 2023 |